Samsung Bioepis Moves Swiftly To Denosumab Phase III

SB16 Biosimilar Rival To Prolia Progresses To Phase III Trials

 
• By David Wallace
  
Clinical Trial
Samsung Bioepis’ SB16 Denosumab Biosimilar Moves To Phase III • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products